BCRXBioCryst Pharmaceuticals, Inc.
Is the price fair?
Modest expectations priced in. That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Priced for a decline (~−13% a year). The price demands less than its three-year revenue growth of 45% a year, expectations look modest.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What BCRX's price assumes
BioCryst Pharmaceuticals, Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is measured against sales instead: 2.82× revenue.
Price / sales · no P/E: the last twelve months did not end in a profit
- Free cash flow yield
- 19%
Free cash flow yield · Drug Manufacturers - Specialty & Generic median 4.9%
- Growth the price implies
- −13%
Growth the price implies · The price pays for −13% free cash flow growth a year for a decade; revenue has grown 45% a year over the last three.
- EV / sales
- 2.86
EV / sales
Details›
- EV / EBIToperating margin −33%: the multiple describes the denominator
- not meaningful
- EV / salesas of 2026-Q2
- 2.86
- Free cash flow, trailing twelve months
- $373M
- Market capitalisation255.5 million shares, counted Jul 31, 2026
- $1.95B
- 3-year revenue growth
- +45%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
What is it worth?
Today's price against what its own multiples, its cash flow and your growth assumption say it is worth.
Drug Manufacturers, Specialty & Generic
Ranks #34 of 39 by RyuScore